Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 13/20 | 0.63 |
| ▸ | TNF | P01375 | 3/20 | 0.63 |
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974860 | 1.00 | IL1B (0.63) | IL1BTNFNLRP3KCNH2CHEK1 | |
| SCHEMBL24695700 | 0.87 | IL1B (0.69) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL26132225 | 0.87 | IL1B (0.69) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL29326368 | 0.87 | IL1B (0.69) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL30054549 | 0.87 | IL1B (0.69) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL29326389 | 0.87 | IL1B (0.69) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL29326766 | 0.85 | IL1B (0.48) | IL1BTNFNLRP3CHEK2 | |
| SCHEMBL29326772 | 0.85 | IL1B (0.65) | IL1BTNFNLRP3KCNH2 | |
| SCHEMBL29326775 | 0.85 | IL1B (0.61) | IL1BTNFNLRP3 | |
| SCHEMBL29326777 | 0.83 | IL1B (0.46) | IL1BTNFNLRP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | IL1B 11/4885TNF 67/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.